Vetigenics Doses First Patient in CHECKMATE K9 Study Evaluating VGS 001 + VGS 002 in Dogs with Solid Tumors

Shots:

• Vetigenics initiated dosing in a multisite CHECKMATE K9 pilot study evaluating the safety and preliminary efficacy of VGS 001 (anti‑cCTLA‑4 mAb) + VGS 002 (anti‑cPD‑1 mAb) in dogs with various solid tumors
• Early data from single-agent use demonstrated strong safety and encouraging therapeutic responses in Dogs
• VGS 001 is an anti‑cCTLA‑4 mAb and VGS 002 is an anti‑cPD‑1 mAb being evaluated for various solid tumors

Ref: PRNewswire | Image: Vetigenics| Press Release

Related News:- Gilead Sciences and Kymera Therapeutics Sign Exclusive Option and License Agreement to Develop Oral CDK2 Degraders

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com